DRREDDY1,141.00

Dr. Reddy's Laboratories Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMACIPLALUPINAPOLLOHOSPMAXHEALTHDIVISLABTORNTPHARMZYDUSLIFEMcap ₹95,274 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
DRREDDY
FY26
SUNPHARMA
FY26
CIPLA
FY26
LUPIN
FY26
Peer
Median
Valuation — at last close
P/E22.63×38.70×28.61×17.76×28.61× -21%
P/B2.49×5.29×3.22×4.21×4.21× -41%
EV/EBITDA14.91×23.53×17.43×10.55×17.43× -14%
Market Cap₹95,274 Cr₹4.44L Cr₹1.11L Cr₹94,823 Cr₹1.11L Cr -14%
Growth
Revenue CAGR 3Y10.96%10.03%7.37%18.88%10.03% +9%
Revenue CAGR 5Y12.09%11.78%8.01%13.02%11.78% +3%
Net Income CAGR 3Y-2.66%10.57%10.88%128.70%10.88% -124%
Revenue YoY (latest Q)-5.51%10.46%2.33%32.04%10.46% -153%
Net Income YoY (latest Q)-69.10%26.53%-39.18%16.01%16.01% -532%
Profitability
EBITDA Margin19.15%30.33%20.89%31.53%30.33% -37%
Net Income Margin12.34%19.69%13.71%19.16%19.16% -36%
Return on Common Equity10.98%13.69%11.24%23.69%13.69% -20%
Return on Capital Employed10.62%17.17%13.17%28.94%17.17% -38%
Return on Assets7.15%10.58%9.09%13.96%10.58% -32%
Credit & Quality
Total Debt/Equity0.16×0.05×0.01×0.26×0.05× +220%
Interest Coverage11.76×43.65×85.90×17.12×43.65× -73%
Scale — latest FY
Revenue / Total Income₹33,700 Cr₹58,462 Cr₹28,163 Cr₹27,958 Cr₹28,163 Cr +20%
Net Income₹4,158 Cr₹11,509 Cr₹3,862 Cr₹5,355 Cr₹5,355 Cr -22%
Total Assets₹58,123 Cr₹1.09L Cr₹42,496 Cr₹38,365 Cr₹42,496 Cr +37%
EPS₹50.41₹47.8₹48.03₹116.75₹48.03 +5%
Book Value per Share₹457.86₹349.6₹427.34₹492.42₹427.34 +7%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.